National Study Help Re-Define Low-Grade Brain Tumor Diagnosis
DETROIT, June 25, 2015 /PRNewswire/ — Sixty-seven patients from the Hermelin Brain Tumor Center at Henry Ford Hospital and their families made important contributions to a national cancer study that proposes a change in how some brain tumors are classified – and ultimately treated.
Published in the July 25 issue of the New England Journal of Medicine, the study reveals that a tumor’s DNA – not just tumor stage and what the affected cells look like under a microscope – is key to determining if a lower-grade malignant brain tumor (glioma) may rapidly progress to glioblastoma, the most common and deadliest form of malignant brain cancer. Learn more about the Hermelin Brain Tumor Center at HenryFord.com/Neuro.
Medtronic (NYSE: MDT) announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of the Advisa SR MRI SureScan single-chamber pacemaker with the 5076 MRI lead, which allows for magnetic resonance imaging (MRI) scans positioned on any region of the body without restrictions. The new system includes the Advisa SR MRI pacemaker and a SureScan lead, which must be used together to be considered MR-conditional.
SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics
MILFORD, Mass., June 26, 2015 /PRNewswire/ — SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, to create reference materials and positive controls for cancer assays. The CRADA will investigate the development of methods to mix and accurately quantitate control DNA biosynthetics spiked into a genomic DNA background and cell-free circulating tumor DNA (ctDNA) for next-generation DNA sequencing (NGS) applications.
Aratana Therapeutics Announces Positive Pivotal Results for AT-002
KANSAS CITY, Kan., June 26, 2015 /PRNewswire/ — Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced positive results from its pivotal field effectiveness study of capromorelin (AT-002), the company’s innovative therapeutic for appetite stimulation in dogs. Capromorelin is a small molecule that mimics ghrelin, the naturally occurring hormone that stimulates appetite, increases body weight and increases serum growth hormone levels.